Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3944 | Telmisartan 20 mg/amlodipine 2.5 mg . Wiki | 0.71 |
| drug270 | Amlodipine 2.5 mg/indapamide 1.25 mg Wiki | 0.71 |
| drug3946 | Telmisartan 20 mg/indapamide 1.25 mg Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4774 | telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg Wiki | 0.71 |
| drug4773 | telmisartan 40 mg/amlodipine 5 mg Wiki | 0.71 |
| drug3943 | Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg Wiki | 0.71 |
| drug4369 | amlodipine 5 mg/indapamide 2.5 mg Wiki | 0.71 |
| drug4775 | telmisartan 40 mg/indapamide 2.5 mg Wiki | 0.71 |
| drug2916 | Placebo Wiki | 0.03 |
Navigate: Correlations HPO
There are 2 clinical trials
Recent hypertension guidelines recommend combination therapy as initial treatment for many or most patients. Several trials suggest triple low-dose combination therapy may be highly effective in terms of achieving blood pressure control without increasing adverse effects. This trial is designed to investigate the efficacy and safety of GMRx2 in participants with high blood pressure compared to dual combinations.
Description: Percentage of participants discontinued trial medication due to AE/SAE from baseline to week 12
Measure: Safety Outcomes Time: 12 weeksDescription: Percentage of participants discontinued trial medication due to AE/SAE from baseline to Week 6
Measure: Safety Outcomes Time: 6 weeksDescription: Percentage of participants with an SAE from baseline to Week 12
Measure: Safety Outcomes Time: 12 weeksDescription: Percentage of participants with SAE from baseline to Week 6
Measure: Safety Outcomes Time: 6 weeksDescription: Percentage of participants with symptomatic hypotension from baseline to Week 12
Measure: Safety Outcomes Time: 12 weeksDescription: Percentage of participants with symptomatic hypotension from baseline to Week 6
Measure: Safety Outcomes Time: 6 weeksDescription: Percentage of participants with serum sodium concentration below 135 mmol/l at Week 12
Measure: Safety Outcomes Time: 12 weeksDescription: Percentage of participants with serum sodium concentration below 135 mmol/l at Week 6
Measure: Safety Outcomes Time: 6 weeksDescription: Percentage of participants with serum sodium concentration above 145 mmol/l at Week 12
Measure: Safety Outcomes Time: 12 weeksDescription: Percentage of participants with serum sodium concentration above 145 mmol/l at Week 6
Measure: Safety Outcomes Time: 6 weeksDescription: Percentage of participants with serum potassium concentration below 3.5 mmol/l at Week 12
Measure: Safety Outcomes Time: 12 weeksDescription: Percentage of participants with serum potassium concentration below 3.5 mmol/l at Week 6
Measure: Safety Outcomes Time: 6 weeksDescription: Percentage of participants with serum potassium concentration above 5.5 mmol/l at Week 12
Measure: Safety Outcomes Time: 12 weeksDescription: Percentage of participants with serum potassium concentration above 5.5 mmol/l at Week 6
Measure: Safety Outcomes Time: 6 weeksDescription: Percentage of participants with eGFR drop of over 30% from baseline to Week 12
Measure: Safety Outcomes Time: 12 weeksDescription: Percentage of participants with eGFR drop of over 30% from baseline to Week 6
Measure: Safety Outcomes Time: 6 weeksRecent hypertension guidelines recommend combination therapy as initial treatment for many or most patients. Several trials suggest triple low-dose combination therapy may be highly effective in terms of achieving blood pressure control without increasing adverse effects. This trial is designed to investigate the efficacy and safety of GMRx2 in participants with high blood pressure compared to placebo.
Description: Percentage of participants discontinued trial medication due to AE/SAE from baseline to Week 4
Measure: Safety Outcomes Time: 4 weeksDescription: Percentage of participants with an SAE from baseline to Week 4
Measure: Safety Outcomes Time: 4 weeksDescription: Percentage of participants with symptomatic hypotension from baseline to Week 4
Measure: Safety Outcomes Time: 4 weeksDescription: Percentage of participants with serum sodium concentration below 135 mmol/l at Week 4
Measure: Safety Outcomes Time: 4 weeksDescription: Percentage of participants with serum sodium concentration above 145 mmol/l at Week 4
Measure: Safety Outcomes Time: 4 weeksDescription: Percentage of participants with serum potassium concentration below 3.5 mmol/l at Week 4
Measure: Safety Outcomes Time: 4 weeksDescription: Percentage of participants with serum potassium concentration above 5.5 mmol/l at Week 4
Measure: Safety Outcomes Time: 4 weeksDescription: • Percentage of participants with eGFR drop of over 30% from baseline to Week 4
Measure: Safety Outcomes Time: 4 weeksAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports